Bladder cancer Bladder cancer, Urothelial carcinoma
Conditions
Interventions
Interventions for the ERAS group will be conducted in accordance with the study protocol, as described below.
1. Study explanation and initiation of the herbal medicine
On the day of intervention ini
D010371
Enhanced Recovery After Surgery, ERAS, perioperative care, RARC, radical cystectomy
Sponsors
Inoue Takahiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with bladder cancer for whom radical cystectomy is indicated. 2. Patients planning to undergo robot-assisted radical cystectomy with urinary diversion at our institution. 3. Patients aged 18 years or older at the time of enrollment. 4. Patients who have provided written informed consent based on their own free will after receiving sufficient explanation of the study.
Exclusion criteria
Exclusion criteria: 1. Patients who are expected to be unable to undergo standard oral intake or rehabilitation during the perioperative period. 2. Patients with incomplete medical records that prevent confirmation of postoperative treatment history or recurrence status (applicable to the retrospective cohort). 3. Patients who received non-insurance-covered treatments or investigational drugs for the treatment of urothelial carcinoma. 4. Patients deemed inappropriate for inclusion in the study by the principal investigator or sub-investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Length of Stay; LOS | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative complications of Clavien-Dindo classification grade II or higher and their incidence within 30 days Postoperative complications of Clavien-Dindo classification grade III or higher and their incidence within 30 days Readmission rate due to postoperative complications within 90 days Barthel Index (BI): preoperatively, postoperative day (POD) 1, POD 3 plus or minus 1, POD 7 plus or minus 2, POD 14 plus or minus 3, and at discharge Short Physical Performance Battery (SPPB): preoperatively, POD 7 plus or minus 2, POD 14 plus or minus 3, and at discharge Handgrip strength: preoperatively, POD 7 plus or minus 2, POD 14 plus or minus 3, and at discharge ECOG Performance Status (ECOG-PS), G8 screening tool, and the Japanese version of the Cardiovascular Health Study (CHS) criteria: at study entry, at hospital admission, at discharge, POD 30 plus or minus 7, and POD 90 plus or minus 14 Time to first flatus and time to first bowel movement Psoas muscle area and mean psoas muscle CT attenuation at the L3 vertebral level Duration of Ninjin'yoeito administration, medication adherence, and treatment-related adverse events such as hypokalemia, hepatic dysfunction, and edema Medically ready for discharge (MRD) | — |
Contacts
Public ContactYusuke Sugino
Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine.
Outcome results
None listed